Re: Lymphoseek Approval
Since the shinanagins have continued, I have programmed myself to accept that our shares "could" remain underpriced in the $4 or $5 range. If they do, the lid blows off after the second quarter of new revenues hits the bottom line. Only a fool would want to be on the outside looking in if the P/E was 10 to 1 when revenues were going parabolic. Shorts? They should be our bestest buddies fairly soon. Think of them as a built in hydrolic system to price under a lot of pressure.